A library of over 20 cycloplatinated compounds of the type [Pt(dmba-R)LCl] (dmba-R = C,N-dimethylbenzylamine like ligand; R being MeO, Me, H, Br, F, CF3 and NO2 substituents in the R5 or R4 position of the phenyl ring; L = DMSO and P(C6H4CF3-p)3 has been prepared. All compounds are active in both human ovarian carcinoma A2780 cells and the cisplatin-resistant A2780cisR cells, with most of the DMSO platinum complexes exhibiting IC50 values in the sub-micromolar range in A2780 cell line. Interestingly, DMSO platinum complexes show low cytotoxicity in the non-tumorigenic kidney cell line BGM and therefore high selectivity factors SF. In addition, some of the DMSO platinum complexes effectively inhibit angiogenesis in the human umbilical vein endothelial cell line EA.hy926. These are the first platinum(II) complexes reported to inhibit angiogenesis at a close concentration to their IC50 in A2780 cells, turning them into dual cytotoxic and anti-angiogenic compounds.